GlassScriptPhysician profile
Devjani Lahiri-Munir
NPI 1841371341
$5,023.04
in general payments reported to CMS, 2019-2025
21 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $45.33 · 2021: $317 · 2022: $695 · 2023: $1,165 · 2024: $841 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,193.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $855.87 | 2019-2024 | Total30 |
| Glaukos Corporation | $523.98 | 2022-2023 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem |
| Abbvie INC. | $474.27 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $388.58 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $361.26 | 2021-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $360.55 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Lumenis Be INC | $252.05 | 2023 | Optilight |
| Allergan, INC. | $245.20 | 2020-2022 | |
| Dompe US, INC. | $242.26 | 2024-2025 | Oxervate |
| Astellas Pharma US INC | $201.38 | 2023-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $150.24 | 2024-2025 | Acthar |
| Carl Zeiss Meditec USA, INC. | $140.28 | 2023 | Cirrus Hd-Oct |
| Sun Pharmaceutical Industries INC. | $128.09 | 2020-2023 | Cequa |
| Horizon Therapeutics Plc | $116.12 | 2022 | |
| Biotissue Holdings INC. | $115.01 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $112.11 | 2022-2023 | |
| Coopervision INC. | $86.64 | 2022 | |
| Optos, INC. | $83.18 | 2021 | |
| Oyster Point Pharma, INC. | $72.22 | 2022-2024 | Tyrvaya |
| Genentech USA, INC. | $63.68 | 2019 | |
| Harrow Eye, LLC | $50.07 | 2024-2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devjani Lahiri-Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.